Cahir MedTech
All insights

NTAP Cost Threshold Explained: How to Check CMS Thresholds for Your MS-DRG (FY 2028)

Learn how the CMS NTAP cost threshold works, how to check your MS-DRG for FY 2028 applications, how the 65% add-on is calculated, and common mistakes.

NTAP Cost Threshold Explained: How to Check CMS Thresholds for Your MS-DRG (FY 2028)

The NTAP cost threshold is the average charge per case, set by CMS for each MS-DRG every fiscal year, that a new technology's cases must exceed to qualify for a New Technology Add-on Payment. Device teams check it by finding their MS-DRG in the IPPS final rule threshold table and comparing it with their estimated charges per case, including the device.

This guide explains how the cost test works, what CMS publishes, and where teams go wrong. To check a real MS-DRG in seconds, use the free NTAP cost threshold check in MedTech Compass.

The three NTAP tests

Under 42 CFR 412.87, a technology must pass three tests to receive NTAP:

1. **Newness.** The technology is new, generally within two to three years of market entry, and not substantially similar to an existing technology. 2. **Cost.** Average charges for cases using the technology exceed the threshold CMS sets for the MS-DRG those cases group to. 3. **Substantial clinical improvement.** The technology substantially improves diagnosis or treatment compared with existing options. Certain FDA Breakthrough Devices and qualified antimicrobial products can use an alternative pathway that does not require this showing.

The cost test is the one teams can model early, before clinical data is final. That makes it the natural first check.

Where the thresholds come from

CMS publishes the cost thresholds with each IPPS final rule. The FY 2027 IPPS Final Rule carries the thresholds that apply to FY 2028 NTAP applications. Each MS-DRG has its own threshold, so the same device can pass in one DRG and fail in another.

CMS compares thresholds to **charges**, not costs. Hospital charges are usually far higher than the device price, so a team must estimate the full average charge per case, including the device, standard of care and length of stay, before comparing.

How to check your MS-DRG

1. Identify the MS-DRGs your target cases group to. Many devices span a family (with MCC, with CC, without CC/MCC). 2. Estimate average charges per case including the device, based on claims analysis or a defensible build-up. 3. Compare each estimate with that MS-DRG's published threshold. 4. Repeat for every DRG in the family; CMS evaluates the cases you present.

The free threshold check does steps 3 and 4 for any MS-DRG against the official CMS values.

Illustrative example

The figures below are hypothetical and only show the logic. They are not CMS thresholds.

Swipe horizontally to see all columns.

MS-DRG (illustrative)Threshold (hypothetical)Estimated charges per caseResult
Family A, with MCC$180,000$205,000Likely clears
Family A, with CC$150,000$142,000Likely does not clear
Family A, without CC/MCC$120,000$131,000Likely clears

Mixed results like this are common. They change which DRG data you emphasize in the application and how you describe the patient population.

How the add-on payment is calculated

If CMS approves NTAP, 42 CFR 412.88 generally pays the lesser of 65% of the technology's cost or 65% of the amount by which the case's costs exceed the standard MS-DRG payment (75% for certain qualifying antimicrobial products). Passing the threshold earns eligibility to be considered, not a set dollar amount.

FY 2028 timeline

  • **October 2026:** FY 2028 NTAP applications are typically due in early to mid October.
  • **Spring 2027:** CMS discusses applicants in the IPPS proposed rule and takes public comment.
  • **May 1, 2027:** FDA marketing authorization is generally needed by this date (July 1 for Breakthrough Devices).
  • **August 2027:** The IPPS final rule announces approvals and the next cycle's thresholds.
  • **October 1, 2027:** Payments begin for FY 2028 discharges.

Confirm dates on the CMS NTAP page each cycle.

Three common mistakes

1. **Comparing device price to the threshold.** The test uses total charges per case, not the device's list price. 2. **Checking one DRG.** Devices often group to a family of MS-DRGs; a single check can hide a failing DRG. 3. **Using last year's table.** Thresholds change every fiscal year. Use the table that applies to your application cycle.

Going further

The free check answers "do we likely clear?" The full analysis in MedTech Compass adds five years of Medicare DRG discharge volumes, CMS payment weights, the estimated NTAP add-on payment per case and a branded PDF for your team. To build the charge, threshold and hospital margin case yourself, use the NTAP Master Workbook ($499 one-time Excel workbook). For coding, coverage and payer planning, see the Reimbursement & Coding toolkit and our market access guide.

NTAP questions

What is the NTAP cost threshold?

It is the minimum average charge per case, set by CMS for each MS-DRG every fiscal year, that a new technology's cases must exceed to meet the NTAP cost criterion. CMS publishes the thresholds with the IPPS final rule.

Does meeting the cost threshold guarantee NTAP?

No. Cost is one of three tests. CMS also requires that the technology is new and offers a substantial clinical improvement, unless an alternative pathway such as Breakthrough Device designation applies.

How much does NTAP pay?

Generally the lesser of 65% of the technology's cost or 65% of the amount by which the case's costs exceed the standard MS-DRG payment, under 42 CFR 412.88.

When are NTAP applications due?

Applications are typically due in October for the next fiscal year, with decisions in the IPPS final rule around August and payments from October 1.

Sources

This article is educational and current as of November 11, 2026. It is not reimbursement advice; confirm NTAP strategy with qualified reimbursement advisors.

New to a term? See the MedTech regulatory glossary for plain-English definitions.

Share thisLinkedInXEmail

Follow MedTech Insights

New articles on FDA 510(k) and De Novo pathways, CE Mark and EU MDR, and device reimbursement — sent to your inbox as they publish.

See the CAHIR MedTech Suite in action

Request a demo